Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era

References

• Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10 × ’20 Progress – development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013;56(12):1685-94
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1-12
   PubMed Web of Science ®Google Scholar
• Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Updat 2011;14(2):118-24
   PubMed Web of Science ®Google Scholar
• Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113(Suppl 1A):5S-13S
   PubMed Web of Science ®Google Scholar
• Harbarth S, Filius PM, Natsch S, et al. On behalf of the ESCMID Study Group on Antibiotic Policies. Shortage of antimicrobial agents in Europe: results of an International Survey 2007. Available from: http://www.escmid.org/fileadmin/srs/media/PDFs/3Research_Projects/ESGAP/ESGAP_Poster_ECCMIDO7_on_Antibiotic_Drug_Shortage.pdf. [Last accessed 18 November 2013]
   Google Scholar
• Pulcini C, Bush K, Craig WA, et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 2012;54(2):268-74
   PubMed Web of Science ®Google Scholar
• Nicolle LE. Epidemiology of urinary tract infection. Infect Med 2001;18:153-62
   Google Scholar
• Orenstein R, Wong ES. Urinary tract infections in adults. Am Fam Physician 1999;59(5):1225-34; 1237
   PubMed Web of Science ®Google Scholar
• Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13 2011;169:1-38
   Google Scholar
• Ruben FL, Dearwater SR, Norden CW, et al. Clinical infections in the noninstitutionalized geriatric age group: methods utilized and incidence of infections. The Pittsburgh Good Health Study. Am J Epidemiol 1995;141(2):145-57
   Google Scholar
• Gleckman R, Alvarez S, Joubert DW, Matthews SJ. Drug therapy reviews: methenamine mandelate and methenamine hippurate. Am J Hosp Pharm 1979;36(11):1509-12
   Google Scholar
• Hilbert DW. Chapter 11: Antibiotic resistance in urinary tract infections: current issues and future solutions. In: Tenke P, editor. Urinary tract infections. InTech, Croatia; 2011. p. 193-206. Online Edition Available from: www.intechopen.com
   Google Scholar
• AHFS. Available from: www.ahfsdruginformation.com/support/not_in_print/a382296.aspx [Accessed 16 July 2013]
   Google Scholar
• Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am 2003;17(2):243-59
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006;27(6):468-75
   PubMed Web of Science ®Google Scholar
• Musher DM, Griffith DP. Generation of formaldehyde from methenamine: effect of pH and concentration, and antibacterial effect. Antimicrob Agents Chemother 1974;6(6):708-11
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control/European Medicines Agency (ECDC/EMEA). The bacterial challenge: time to react – a call to narrow the gap between multidrug-resistant bacterial in the EU and the development of new antibacterial agents. Joint Technical Report, September 2009. Available from: http://www.ema.europa.edu/docs/en_GB/document_library/Report/2009/11/WC500008770.pdf
   Google Scholar
• Kevorkian CG, Merritt JL, Ilstrup DM. Methenamine mandelate with acidification: an effective urinary antiseptic in patients with neurogenic bladder. Mayo Clin Proc 1984;59(8):523-9
   Google Scholar
• Urex^® [package insert]. Vatring Pharmaceuticals, Inc; Wytheville, VA, USA: 2004
   Google Scholar
• Hiprex^® [package insert]. Sanifi-Aventis U.S. LLC; Bridgewater, NJ, USA: 2006
   Google Scholar
• Mandelamine^® (Methenamine Hippurate) [package insert]. Warner Chilcott; Rockaway, NJ, USA: 2006
   Google Scholar
• Hooper DC. Chapter 37: Urinary tract agents: nitrofurantoin and methenamine. In: Mandell GL, Bennett JE, Dolin R, editor. Mandell, douglas, and bennett’s principles and practice of infectious diseases. ELSEVIER Churchill Livingstone; Philadelphia, PA, USA: 2010. p. 515-20
   Google Scholar
• Duca CJ, Scudi JV. Some antibacterial properties of mandelamine (methenamine mandelate). Proc Soc Exp Biol Med 1947;66(1):123-6
   Google Scholar
• Petri WA J. Sulfonamides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections. In: Brunton L, Chabner B, Knollmann B, editors. Goodman & Gilman’s the pharmacological basis of therapeutics (12th Edition). McGraw Hill Medical, New York, NY, USA; 2011. p. 1413-76
   Google Scholar
• Musher DM, Griffith DP, Tyler M, Woelfel A. Potentiation of the antibacterial effect of methenamine by acetohydroxamic acid. Antimicrob Agents Chemother 1974;5(2):101-5
   Google Scholar
• Hamilton-Miller JM, Brumfitt W. Methenamine and its salts as urinary tract antiseptics: variables affecting the antibacterial activity of formaldehyde, mandelic acid, and hippuric acid in vitro. Invest Urol 1977;14(4):287-91
   PubMedGoogle Scholar
• Klinge E, Mannisto P, Mantyla R, et al. Pharmacokinetics of methenamine in healthy volunteers. J Antimicrob Chemother 1982;9(3):209-16
   Google Scholar
• Mayrer AR, Andriole VT. Urinary tract antiseptics. Med Clin North Am 1982;66(1):199-208
   Google Scholar
• Thomas LD, Elinder CG, Tiselius HG, et al. Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med 2013;173(5):386-8
   Google Scholar
• Nahata MC, Cummins BA, McLeod DC, et al. Effect of urinary acidifiers on formaldehyde concentration and efficacy with methenamine therapy. Eur J Clin Pharmacol 1982;22(3):281-4
   PubMed Web of Science ®Google Scholar
• Cronberg S, Welin CO, Henriksson L, et al. Prevention of recurrent acute cystitis by methenamine hippurate: double blind controlled crossover long term study. Br Med J (Clin Res Ed) 1987;294(6586):1507-8
   PubMed Web of Science ®Google Scholar
• Harding GK, Ronald AR. A controlled study of antimicrobial prophylaxis of recurrent urinary infection in women. N Engl J Med 1974;291(12):597-601
   PubMed Web of Science ®Google Scholar
• Everaert K, Lumen N, Kerckhaert W, et al. Urinary tract infections in spinal cord injury: prevention and treatment guidelines. Acta Clin Belg 2009;64(4):335-40
   PubMed Web of Science ®Google Scholar
• Vainrub B, Musher DM. Lack of effect of methenamine in suppression of, or prophylaxis against, chronic urinary infection. Antimicrob Agents Chemother 1977;12(5):625-9
   PubMed Web of Science ®Google Scholar
• Lee BS, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev 2012;10:CD003265
   PubMed Web of Science ®Google Scholar
• Strom JG Jr, Jun HW. Effect of urine pH and ascorbic acid on the rate of conversion of methenamine to formaldehyde. Biopharm Drug Dispos 1993;14(1):61-9
   Google Scholar
• Selvaag E, Thune P. Photosensitivity reaction to methenamine hippurate. A case report. Photodermatol Photoimmunol Photomed 1994;10(6):259-60
   Google Scholar
• Elo J, Sarna S, Ahava K, Lepo A. Methenamine hippurate in urinary tract infections in children: prophylaxis, treatment and side effects. J Antimicrob Chemother 1978;4(4):355-65
   Google Scholar
• Petersen S. Long-term prophylaxis with methenamine hippurate in girls with recurrent urinary tract infections. Acta Paediatr Scand 1978;67(5):597-9
   Google Scholar
• Allgen LG, Holmberg G, Persson B, Sorbo B. Biological fate of methenamine in man. Absorption, renal excretion and passage to umbilical cord blood, amniotic fluid and breast milk. Acta Obstet Gynecol Scand 1979;58(3):287-93
   Web of Science ®Google Scholar
• Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46(2):155-64
   PubMed Web of Science ®Google Scholar
• Sundqvist M, Geli P, Andersson DI, et al. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemother 2010;65(2):350-60
   PubMed Web of Science ®Google Scholar
• Burke JP. Antibiotic resistance–squeezing the balloon? JAMA 1998;280(14):1270-1
   PubMed Web of Science ®Google Scholar
• Union of Concerned Scientists. Prescription for trouble: using antibiotics to fatten livestock. Available from: http://www.ucsusa.org/food_and_agriculture/our-failing-food-system/industrial-agriculture/prescription-for-trouble.html [Last accessed 13 December 2013]
   Google Scholar
• Mitka M. Indian public health leaders move to reduce antimicrobial resistance. JAMA 2013;309(6):531-2
   Google Scholar
• Delepierre A, Gayot A, Carpentier A. Update on counterfeit antibiotics worldwide; public health risks. Med Mal Infect 2012;42(6):247-55
   PubMed Web of Science ®Google Scholar
• The World Academy of Sciences. Return to. pre-antibiotic era? Available from: http://twas.ictp.it/news-in-home-page/news/iap_iamp_amr [Accessed 13 December 2013]
   Google Scholar